David Devos, Doctor of Neurology, Doctor of Neuroscience and Professor in Medical Pharmacology CHU, University of Lille, INSERM U1172

“Brain infusion of anaerobic dopamine for Parkinson’s disease: DIVE-I study”

Dr. Devos domain of research concerns development of innovative therapeutic strategies in neurodegenerative diseases from the concept through in vitro, in vivo research to large clinical trials. He published more than 240 articles (New England J Medicine, Lancet Neurol, Brain…), H-index of 60, obtained several awards: European Pharmacology Scientific Award, University Foundation, I-SITE-ULNE, ILAB, DeepTech Price, Price of European Stars..., obtained 5 patents leading to 2 industrial transfers for which he cofounded 2 Start up being spin off of the research team, participated in 31 studies including 14 multicenter trials and 14 as Coordinator, 4 European Commission funded projects (H2020) including 2 in neurosciences (iron, ferroptotic cell death), 1 large European clinical trial FAIRPARK-2 http://www.fairpark2.eu/people/david-devos and 1 on diagnosis on Covid-19. Career competitive research funding > 12M€. He is coordinating the neurogenetic center of Lille (Spinocerebellar ataxia, spastic paraplegia, Neurodegeneration with Brain Iron Accumulation). He is consultant and running research at the expert center of Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS) of Lille. He is co-coordinating the French network of PD (NS-Park-F-CRIN) and of ALS (ACT4ALS-MND). Scopus Author ID: 7004062843 ; Researcher ID: E-4059-2013 ; ORCID Number: 0000-0002-2417-799X

Lecture host: Per Odin

Light refreshments will be served after the lecture.